Oct. 17 at 5:13 AM
🌅 4:00am EST Watchlist
$ARTV – Next autoimmune focus: refractory RA with NK-cell platform. Plans for first-in-autoimmune study; watch design (dose, DAS28/CDAI), site timing, and any partnering updates. Steroid-sparing and combo angles in play.
$AKAN – Initiative to accelerate recurring revenue via expansion up to 20 towers for high-density production. Modular footprint, improved unit economics, and phased offtakes aimed at steady B2B/B2C contracts.
$KZR – Reg update on zetomipzomib in AIH plus exploring strategic alternatives (partnerships, assets, M&A). Near term: AIH study requirements, pipeline reprioritization, banker engagement.
$FEMY – Will exhibit at ASRM 2025; spotlight FemaSeed, FemBloc, and diagnostics. Non-revenue event but KOL engagement and adoption catalyst; watch physician feedback and distributor interest.
$BIAF – Potential multi-day runner. Monitor premarket volume, VWAP reclaims, and prior HOD retests.